OTCMKTS:ALPMY Astellas Pharma 4/25/2024 Earnings Report $9.69 +0.07 (+0.73%) As of 05/23/2025 03:58 PM Eastern ProfileEarnings History Astellas Pharma EPS ResultsActual EPS$0.11Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAstellas Pharma Revenue ResultsActual Revenue$2.79 billionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAstellas Pharma Announcement DetailsQuarterDate4/25/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsAstellas Pharma's next earnings date is estimated for Thursday, August 7, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Astellas Pharma Earnings HeadlinesAstellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna BioMay 21, 2025 | prnewswire.comAstellas CEO Says Engaging With Activist Investor FarallonMay 7, 2025 | bloomberg.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.May 25, 2025 | Timothy Sykes (Ad)Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual CongressesMay 1, 2025 | prnewswire.comAstellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call TranscriptApril 28, 2025 | seekingalpha.comAstellas Pharma and JFCR partner for oncology researchApril 3, 2025 | msn.comSee More Astellas Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Astellas Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your email. Email Address About Astellas PharmaAstellas Pharma (OTCMKTS:ALPMY) manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.View Astellas Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout? Upcoming Earnings PDD (5/27/2025)AutoZone (5/27/2025)Bank of Nova Scotia (5/27/2025)NVIDIA (5/28/2025)Synopsys (5/28/2025)Bank of Montreal (5/28/2025)Salesforce (5/28/2025)Haleon (5/28/2025)Costco Wholesale (5/29/2025)Marvell Technology (5/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
